US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

29.52

+0.64002.22%

Post-market: 31.481.96+6.64%19:58 EDT

Volume:267.06K

Turnover:7.92M

Market Cap:813.07M

PE:-12.62

High:30.48

Open:29.47

Low:29.00

Close:28.88

Loading ...

Overview Company News Filings

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Context Therapeutics presents preclinical data on CT-95

HC Wainwright Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $74

MT Newswires Live

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments

Addex Therapeutics enters collaboration with Sinntaxis AB

PYC Therapeutics Limited (PYC) Gets a Buy from Canaccord Genuity

Addex Therapeutics Partners with Sinntaxis for Brain Injury Recovery Research

Marker Therapeutics Advances T Cell Therapies in 2024

Rakovina Therapeutics Strengthens Board with Strategic Appointments

Major Shareholder Sells Millions in Acrivon Therapeutics Stock!

Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)

Tryptamine Therapeutics to Launch Pioneering Clinical Trial for Binge Eating Disorder

Argenica Therapeutics Advances Phase 2 Trial for Stroke Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":29.52,"timestamp":1746216000000,"preClose":28.88,"halted":0,"volume":267060,"hourTrading":{"tag":"盘后","latestPrice":31.48,"preClose":29.52,"latestTime":"19:58 EDT","volume":1509,"amount":45729.62,"timestamp":1746230322072},"delay":0,"floatShares":11211113,"shares":27543120,"eps":-2.338654,"marketStatus":"Market Closed","change":0.64,"latestTime":"05-02 16:00:00 EDT","open":29.47,"high":30.48,"low":28.995,"amount":7922115.910800001,"amplitude":0.05142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":28.88,"preHourTrading":{"tag":"盘前","latestPrice":28.97,"preClose":28.88,"latestTime":"09:10 EDT","volume":389,"amount":11193.120232,"timestamp":1746191404853},"postHourTrading":{"tag":"盘后","latestPrice":31.48,"preClose":29.52,"latestTime":"19:58 EDT","volume":1509,"amount":45729.62,"timestamp":1746230322072},"volumeRatio":1.2100676767811132,"optionData":{"bulkOrders":[{"symbol":"LENZ","call":true,"expireDate":1752811200000,"strike":"30.0","timestamp":1746204991322,"price":2.85,"volume":2000,"amount":570000,"type":"-"}]},"impliedVol":0.468,"impliedVolPercentile":0.5882},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11211113,"roa":"-25.64%","roe":"-38.94%","lyrEps":-2.338654,"volumeRatio":1.2100676767811132,"shares":27543120,"dividePrice":0,"high":30.48,"amplitude":0.05142,"preClose":28.88,"low":28.995,"week52Low":14.42,"pbRate":"3.98","week52High":38.93,"institutionHeld":0,"latestPrice":29.52,"eps":-2.338654,"divideRate":0,"volume":267060,"delay":0,"ttmEps":-2.338654,"open":29.47,"prevYearClose":28.87,"prevWeekClose":26.87,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":26.87,"twentyDayClose":23,"sixtyDayClose":26.79,"earningDate":1746547200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531039959","title":"Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039959?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:45","pubTimestamp":1746013500,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., April 30, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders  30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.Details of the oral and poster presentation are as follows:. Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+. Presenter: Joanne Taylor, Ph.D., Senior Vice President of Research, Gain Therapeutics. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with a >50% increase in glucocerebrosidase  activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-announces-oral-poster-114500593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4023","LENZ","LU1169589451.USD","BK4585","LU1169590202.USD","BK4119","GT","PD","BK4007","BK4588","GANX"],"gpt_icon":0},{"id":"2531037571","title":"CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2531037571","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531037571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:42","pubTimestamp":1746013364,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:GDTC Earnings and Revenue History April 30th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 4.6%. Earnings per share  missed analyst estimates by 12%.The company's shares are up 2.0% from a week ago.We don't want to rain on the parade too much, but we did also find 4 warning signs for CytoMed Therapeutics (2 are significant!) that you need to be mindful of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomed-therapeutics-full-2024-earnings-114244438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GDTC","LENZ"],"gpt_icon":0},{"id":"2531036186","title":"Context Therapeutics presents preclinical data on CT-95","url":"https://stock-news.laohu8.com/highlight/detail?id=2531036186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531036186?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:38","pubTimestamp":1746013116,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-presents-preclinical-data-on-ct-95?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-presents-preclinical-data-on-ct-95?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CNTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2531482035","title":"HC Wainwright Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $74","url":"https://stock-news.laohu8.com/highlight/detail?id=2531482035","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531482035?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:34","pubTimestamp":1746012893,"startTime":"0","endTime":"0","summary":"Springworks Therapeutics (SWTX) has an average rating of Hold and mean price target of $51.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SWTX"],"gpt_icon":0},{"id":"2531035701","title":"Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035701","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531035701?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin. Data supports ongoing Phase 1 clinical trial for CT-95. PHILADELPHIA, April 30, 2025  -- Context Therapeutics Inc.  , a clinical-stage biopharmaceutical company advancing T cell engaging  bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research  Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.Findings from preclinical studies evaluating CT-95 in cancer cell lines and tumor models illustrate the potential of CT-95 to treat mesothelin-positive tumors. Notably, CT-95 has shown to:. Activate T cells without inducing broad cytokine release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-presents-preclinical-translational-113000360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","CNTX"],"gpt_icon":0},{"id":"2531381160","title":"Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531381160","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531381160?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:11","pubTimestamp":1746011478,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 70.37 percent decrease over losses of $(0.27) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45096090/larimar-therapeutics-q1-eps-0-46-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LRMR"],"gpt_icon":0},{"id":"2531803368","title":"Avalo Therapeutics to Participate in The Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531803368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531803368?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avalo-therapeutics-participate-citizens-life-110000521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","AVTX","BK4139"],"gpt_icon":0},{"id":"2531603576","title":"AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531603576","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531603576?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat on Wednesday, May 7, 2025 at 9:00 am ET, and members of management will be available for 1X1 meetings.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/an2-therapeutics-participate-citizens-jmp-110000939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANTX","BK4127","LENZ","BK4007","JMP"],"gpt_icon":0},{"id":"2531039139","title":"Larimar Therapeutics Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039139?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval. BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025. Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025. Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026. Potential for Accelerated Approval Pathway Based on Skin FXN Concentration","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larimar-therapeutics-reports-first-quarter-110000276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","LENZ","BK4181","BK4007","PK","BK4139","LRMR"],"gpt_icon":0},{"id":"2531087017","title":"Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087017","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087017?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:48","pubTimestamp":1746010080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FHTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 06:48 ET (10:48 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHTX","LENZ"],"gpt_icon":0},{"id":"2531316082","title":"Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2531316082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531316082?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:16","pubTimestamp":1746008204,"startTime":"0","endTime":"0","summary":"Foghorn Therapeutics (FHTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/foghorn-therapeutics-buy-rating-backed-by-innovative-oncology-approaches-and-promising-clinical-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/foghorn-therapeutics-buy-rating-backed-by-innovative-oncology-approaches-and-promising-clinical-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","FHTX"],"gpt_icon":0},{"id":"2531395086","title":"Addex Therapeutics enters collaboration with Sinntaxis AB","url":"https://stock-news.laohu8.com/highlight/detail?id=2531395086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531395086?lang=en_us&edition=fundamental","pubTime":"2025-04-30 17:40","pubTimestamp":1746006058,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced that it has entered into an option- and collaboration agreement with Sinntaxis AB for an exclusive license to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-enters-collaboration-with-sinntaxis-ab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-enters-collaboration-with-sinntaxis-ab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4590","BK4139","LU0128526141.USD","BK4007","ADXN","AB","LU0029874061.USD","LENZ","BK4598","BK4135"],"gpt_icon":0},{"id":"2531703585","title":"PYC Therapeutics Limited (PYC) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2531703585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531703585?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:09","pubTimestamp":1745996956,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Elyse Shapiro maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) on April 28 and set a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pyc-therapeutics-limited-pyc-gets-a-buy-from-canaccord-genuity-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pyc-therapeutics-limited-pyc-gets-a-buy-from-canaccord-genuity-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531763687","title":"Addex Therapeutics Partners with Sinntaxis for Brain Injury Recovery Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2531763687","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531763687?lang=en_us&edition=fundamental","pubTime":"2025-04-30 13:32","pubTimestamp":1745991179,"startTime":"0","endTime":"0","summary":"An announcement from Addex Therapeutics ( ($CH:ADXN) ) is now available. Addex Therapeutics has entered into a collaboration agreement with Sinntax...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/addex-therapeutics-partners-with-sinntaxis-for-brain-injury-recovery-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/addex-therapeutics-partners-with-sinntaxis-for-brain-injury-recovery-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2531724244","title":"Marker Therapeutics Advances T Cell Therapies in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2531724244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531724244?lang=en_us&edition=fundamental","pubTime":"2025-04-30 11:58","pubTimestamp":1745985484,"startTime":"0","endTime":"0","summary":"Marker Therapeutics ( ($MRKR) ) has released its Q4 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/marker-therapeutics-advances-t-cell-therapies-in-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/marker-therapeutics-advances-t-cell-therapies-in-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2531872349","title":"Rakovina Therapeutics Strengthens Board with Strategic Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2531872349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531872349?lang=en_us&edition=fundamental","pubTime":"2025-04-30 10:32","pubTimestamp":1745980338,"startTime":"0","endTime":"0","summary":"Rakovina Therapeutics Inc ( ($TSE:RKV) ) has issued an update. Rakovina Therapeutics Inc. has strengthened its board of directors by appointing Yev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-strengthens-board-with-strategic-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-strengthens-board-with-strategic-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531372855","title":"Major Shareholder Sells Millions in Acrivon Therapeutics Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2531372855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531372855?lang=en_us&edition=fundamental","pubTime":"2025-04-30 10:09","pubTimestamp":1745978967,"startTime":"0","endTime":"0","summary":"New insider activity at Acrivon Therapeutics, Inc. ( ($ACRV) ) has taken place on April 30, 2025. Significant shareholder Perceptive Advisors LLC h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-millions-in-acrivon-therapeutics-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-millions-in-acrivon-therapeutics-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531748089","title":"Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531748089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531748089?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:18","pubTimestamp":1745972312,"startTime":"0","endTime":"0","summary":"Bell Potter analyst Thomas Wakim maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) today and set a price target of A$2.30...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-pyc-therapeutics-limited-pyc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-pyc-therapeutics-limited-pyc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2531710211","title":"Tryptamine Therapeutics to Launch Pioneering Clinical Trial for Binge Eating Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710211","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710211?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:57","pubTimestamp":1745971046,"startTime":"0","endTime":"0","summary":"An announcement from Tryptamine Therapeutics ( ($AU:TYP) ) is now available. Tryptamine Therapeutics has established a framework for a groundbreaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-to-launch-pioneering-clinical-trial-for-binge-eating-disorder?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-to-launch-pioneering-clinical-trial-for-binge-eating-disorder?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531719089","title":"Argenica Therapeutics Advances Phase 2 Trial for Stroke Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531719089","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531719089?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:28","pubTimestamp":1745965711,"startTime":"0","endTime":"0","summary":"An announcement from Argenica Therapeutics Ltd ( ($AU:AGN) ) is now available. Argenica Therapeutics has made significant progress in its Phase 2 c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenica-therapeutics-advances-phase-2-trial-for-stroke-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenica-therapeutics-advances-phase-2-trial-for-stroke-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":4,"totalSize":254,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"LENZ","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.55,"defaultRemindTime":1746648000000,"name":null,"time":"Post Market","dateTimestamp":1746590400000,"actualEps":null},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-01","current":-15.780748,"percent":0.058366,"low":-16.900596,"twenty":-13.829816,"median":-9.921484,"eighty":-6.439382,"high":-5.069183,"avg":-10.158092,"sd":3.260106,"marketCap":785392066},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-01","current":-15.780748,"twenty":-13.829816,"median":-9.921484,"eighty":-6.439382,"marketCap":785392066}],"updateTime":1746258327566}}}